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Endothelin, a 21-amino-acid peptide, binds to a
specific receptor on vascular smooth muscle cells,
thereby inducing vasoconstriction. Although
plasma levels are not consistently elevated in
hypertension, there is evidence that endothelin has
an important role in its pathogenesis.
Administration of endothelin antagonists has
lowered blood pressure and reduced end-organ
damage in some animal models. It has also
reduced the cross-sectional area of neointima due
both to hypertension and vascular injury.
Coadministration of endothelin and angiotensin II
to rats produced a synergistic hypertensive effect.
Similarly, coadministration of an endothelin
antagonist with an angiotensin converting enzyme
inhibitor resulted in a synergistic lowering of
blood pressure. Several preliminary clinical studies
have been done. The endothelin antagonist
bosentan has decreased vascular resistance and
blood pressure and increased cardiac index in
patients with congestive heart failure. Plasma
endothelin levels are elevated in the acute phase of
myocardial infarction and in chronic heart failure.
The magnitude of this increase, measured 3 days
after patients experienced myocardial infarction,
had a significance at least equal to known risk
factors in predicting 1 year survival. Thus, there
are reasons to believe that endothelin antagonists
may become a useful tool in the management of
various cardiovascular disorders. Am J Hypertens
1998;11:103S–109S © 1998 American Journal of
Hypertension, Ltd.
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The endothelium plays a role in regulatingvascular resistance by releasing substancesthat dilate or constrict blood vessels. Thesesubstances, endothelins, are a family of pep-
tides having potent vasoconstrictive effects. There are
basically three types of endothelin: endothelin-1, en-
dothelin-2, and endothelin-3. They are all formed from
precursors (big endothelin) by enzymatic cleavage
and are all 21–amino-acid peptides with disulfide
bridges (Figure 1). Endothelin-1 and endothelin-2 act
on the endothelin-A (ETA) receptor of smooth muscle
to produce a prolonged contraction and vasoconstric-
tion. Endothelin-3 can also induce vasoconstriction by
binding to the endothelin-B (ETB) receptor on smooth
muscle, but it also acts on the ETB receptors of endo-
thelial cells, where it can actually have the opposite
effect. It has been suggested that, under normal con-
ditions, low concentrations of endothelin stimulate
ETB receptors, thus contributing to the release of en-
dothelium-derived relaxing factors.1 Endothelin-1 is
probably the best studied of this family. When admin-
istered to animals, endothelin-1 causes severe vaso-
constriction.2 The contraction of vascular smooth mus-
cle produced by endothelin-1 may be mediated by an
increase in intracellular calcium, but the details have
not been established.3 Infusion of endothelin-1 into
healthy human volunteers resulted in a 2.5-fold in-
crease in plasma endothelin-1 concentration and a rise
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in blood pressure of approximately 6 mm Hg; in con-
trast, infusion of the same molar concentration of en-
dothelin-3 raised plasma levels of endothelin-3 2.5-
fold, but had no effect on blood pressure.4 Like angio-
tensin II and norepinephrine, endothelin-1 is now
thought to play a role in hemodynamic control. It has
not been proven, however, that endothelin normally
participates in the control of vascular tone, and its role
in hypertension has not been established. Plasma lev-
els of endothelin-1 do not increase significantly during
hypertension in humans or animals.5,6 However, en-
dothelin-1 is increased in the aorta and in mesenteric
arteries of deoxycorticosterone acetate (DOCA)-salt
hypertensive rats, despite normal blood levels. In con-
trast, the vascular tissue of spontaneously hyperten-
sive rats does not have a higher endothelin-1 content.7
There is also substantial vascular hypertrophy in
DOCA-salt hypertensive rats, compared to limited hy-
pertrophy of blood vessels in spontaneously hyperten-
sive rats.8 It is therefore possible that endothelin-1,
which has powerful hypertrophic and mitogenic prop-
erties, could have a causal role in this vascular hyper-
trophy. Endothelin-1 is thought to interact with the
sympathetic nervous system and the renin-angioten-
sin system in the regulation of blood pressure and
sodium metabolism, but the mechanisms of these in-
teractions are unknown. Endothelin-1 may also help
regulate vascular tone by modulating angiotensin con-
verting enzyme levels, since it has been reported that
endothelin stimulates the release of angiotensin II
from mesenteric arteries.9
EFFECTS OF ENDOTHELIN ON
BLOOD PRESSURE
Exogenous endothelin-1 alone in sufficiently high con-
centrations has been reported to increase blood pres-
sure in both humans and experimental animals. Con-
tinuous infusion of endothelin-1 in rats at a rate of 60
mg/kg of body weight/day resulted in a significant
increase in the systolic blood pressure, while 6 mg/
kg/day had no significant effect.2 Yoshida et al10 stud-
ied the effects of endothelin-1 and angiotensin II, sep-
arately and in combination, on blood pressure and
physiologic parameters of Sprague-Dawley rats. Intra-
peritoneal administration of angiotensin II at the rate
of 400 mg/kg/day did not induce a significant change
in systolic blood pressure compared to that of controls
(saline infusion). Nor did continuous infusion of 3
mg/kg/day of endothelin-1 affect systolic blood pres-
sure significantly. However, the combined infusion of
endothelin-1 and angiotensin II at these same concen-
trations and rates produced a significant increase in
systolic blood pressure (Figure 2). The increase was
statistically significant 1 day after the start of the in-
fusion and increased thereafter. After 6 days, systolic
blood pressure was 148.0, 142.7, and 143.5 mm Hg in
rats given angiotensin II, endothelin-1, or saline, re-
spectively, whereas it was 189.0 mm Hg in angiotensin
II plus endothelin-1–infused rats (P , .05 v all other
groups); this is an increase of 32% compared to con-
trols. Angiotensin II, endothelin-1, and the combina-
tion did not result in significant changes in body
weight, fluid retention, urine volume, urinary sodium
excretion, or urinary potassium excretion, suggesting
that the effect on blood pressure was not due to renal
effects. In contrast, in the same study, continuous in-
fusion of norepinephrine (360 mg/kg/day), endothe-
lin-1 (3 mg/kg/day), and the combination norepi-
nephrine plus endothelin-1 did not result in any sig-
nificant changes in systolic blood pressure. However,
sufficiently high infusions of norepinephrine (1.8 mg/
kg/day) have been shown to induce a sustained in-
FIGURE 1. The endothelin system. Big ET-1, precursor of endothelin-1; Big ET-2, precursor of endothelin-2; Big ET-3, precursor of
endothelin-3; ET-1, endothelin-1; ET-2, endothelin-2; ET-3, endothelin-3; ECE, endothelin converting enzyme; ETA, endothelin-A
receptor; ETB, endothelin-B receptor; EC, endothelial cell; SMC, smooth muscle cell. Precursors of endothelin-1, -2, and -3 are
enzymatically converted to endothelin-1, -2, and -3, which bind at receptor sites ETA and ETB as shown.
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crease in systolic blood pressure in rats.11 There have
been reports that endothelin-1 can amplify the hyper-
tensive effect of norepinephrine under certain condi-
tions,12 so the interaction of these peptides is still
unresolved.
ENDOTHELIN AND NEOINTIMA FORMATION
The major problem limiting the long-term effective-
ness of percutaneous transluminal coronary angio-
plasty (PTCA) is the high incidence of neointima for-
mation and vascular restenosis.13,14 Endothelin-1 lev-
els are elevated after PTCA, suggesting that
endothelin-1 is implicated in restenosis. In general,
advanced atherosclerotic lesions are characterized by
large numbers of smooth muscle cells, macrophages,
and T lymphocytes. Angiotensin II and norepineph-
rine are thought to be involved in the development of
neointima, and endothelin-1, a potent mitogen, may
also play a role in the process.
Douglas et al14 investigated the effects of exogenous
endothelin-1, and of blockage of endothelin-1, on neo-
intima formation in both an in vitro model and in
vivo. The addition of endothelin-1 (1 nmol/L) in-
creased neointima formation, as evidenced by a nine-
fold increase in thymidine incorporation in cultured
rat aortic vascular smooth muscle cells. This effect was
inhibited in a dose-dependent manner by the simul-
taneous addition of the endothelin receptor antagonist
SB 209670. Endothelin-1-induced proliferation, as
measured by thymidine incorporation, was com-
pletely inhibited by 0.1 mmol/L of SB 209670. How-
ever, even the maximum concentration of SB 209670
used did not alter cell viability, nor did it change basal
proliferation, implying that the effect was not due to a
general inhibition. Furthermore, addition of SB 209670
in a concentration that completely blocked endothelin-
1-induced proliferation had no effect on proliferation
induced by angiotensin II, fibroblast growth factor, or
platelet-derived growth factor. As part of the same
study, the in vivo effects of endothelin-1 and SB
209670 were determined using balloon angioplasty
performed on the left common carotid artery of
Sprague-Dawley rats. In one set of experiments, rats
were administered endothelin-1 by intraarterial infu-
sion over a 30-min period immediately after balloon
angioplasty. Endothelin-1 infusion (500 pmol/kg
body weight over a 30-min period) significantly in-
creased the amount of neointima formation relative to
controls. The cross-sectional area of the neointima was
73% greater in the endothelin-1-treated group, and
there was a corresponding increase of 53% in the
neointima-to-media ratio. This effect was dose depen-
dent. Other than size, the morphology of lesions from
endothelin-1-treated rats was similar to those treated
with saline. The morphology of undamaged contralat-
eral carotid arteries was not affected by endothelin-1.
In a second experiment, rats were treated either
with SB 209670 or saline beginning 3 days before and
continuing 2 weeks after angioplasty. The arteries
were removed at the end of this period and examined
for neointima formation. Treatment with SB 209670
reduced formation of neointima after balloon angio-
plasty. It did not affect the tunica media, but de-
creased the neointima cross-sectional area by 53% and
the ratio of neointima-to-medial cross-sectional area
by 47% (Figure 3). All animals treated with SB 209670
appeared healthy on gross physical examination, and
there were no differences in body weights between
treated rats and controls, indicating that the inhibitory
effect of SB 209670 was not due to nonselective cyto-
toxicity.14
Several studies have reported that cultured rat and
human vascular smooth muscle proliferation is medi-
ated by the ETA receptor.
15,16 Since endothelin-1 levels
FIGURE 2. Effects of infusion of angiotensin II (AII), endothe-
lin-1 (ET-1), and the combination AII plus ET-1 on systolic blood
pressure in conscious rats. Control vehicle (physiologic saline) is
also shown. Reprinted with permission from Yoshida K et al.10
FIGURE 3. Neointima:media ratio in rats that received either
saline or the endothelin receptor antagonist SB 209670. Results
are given as mean 6 SEM. *P , .05 compared with control
(saline) by ANOVA and Fisher’s protected least-squares differ-
ence. Reprinted with permission from Douglas SA et al.14
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are sharply elevated in the human coronary sinus after
PTCA, it has been suggested that enhanced exposure
of smooth muscle to endothelin-1 may stimulate neo-
intima formation. Thus, endothelin-1 may be derived
from circulating blood or come from damaged endo-
thelial or smooth muscle cells in the vicinity of the
lesion. While the evidence implicates such a mecha-
nism, it has not been definitely established that endo-
thelin-1 has a causal role in restenosis. Because endo-
thelin-1 induces the release of several growth factors,
such as platelet-derived growth factor (PDGF), it may
function as an indirect or comitogen. The increase in
neointima area in response to endothelin-1 is also
interesting considering its short plasma half-life,
which is about 1 min.17 However, unlike angiotensin II
and norepinephrine, the effects of endothelin-1 are
prolonged; the half-life for endothelin-1-receptor dis-
sociation is over 100 h.18
EFFECTS OF BOSENTAN
Most studies with ETA receptor antagonists, such as
BQ-123, found that they produce only moderate low-
ering of blood pressure.19 Bosentan is a recently de-
veloped, long-acting, nonselective endothelin receptor
antagonist. It blocks both ETA and ETB receptors. A
study of DOCA-salt hypertensive rats used bosentan
to examine whether the increase in vascular endothe-
lin contributes to elevated blood pressure and vascu-
lar hypertrophy.1 The rats received bosentan (100
mg/kg body weight/day) in their food for 3 weeks.
The systolic blood pressure of DOCA-salt hyperten-
sive rats increased to 197 mm Hg during the course of
the study, whereas blood pressure of bosentan-treated
rats increased to only 177 mm Hg (P , .01). The
mesenteric resistance arteries of DOCA-salt hyperten-
sive rats had a smaller lumen diameter than those in
uninephrectomized control animals (230 v 271 mm,
P , .01). The arterial lumen diameter in bosentan-
treated DOCA rats was 253 mm, which was signifi-
cantly larger (P , .05) than the diameter (230 mm) in
untreated DOCA rats (Figure 4). The media:lumen
ratio was significantly greater in DOCA rats than in
the controls (7.6% v 3.9%, P , .01); in bosentan-treated
DOCA rats, this parameter was 5.2%, which was sig-
nificantly higher than that of uninephrectomized con-
trols (P , .05) and untreated DOCA rats (P , .01)
(Figure 4). The width of the media and cross-sectional
area of the media of resistance arteries were signifi-
cantly smaller in bosentan-treated rats compared to
untreated DOCA rats. There were no significant dif-
ferences in lumen diameter or the cross-sectional area
of the media of vessels between bosentan-treated rats
and uninephrectomized control rats. The vasoconstric-
tor responses of bosentan-treated rats were nearly
those of controls. Plasma endothelin-1 was signifi-
cantly higher in bosentan-treated rats, possibly indi-
cating that it was being produced but not binding to
its receptor in these animals. These results strongly
suggest that endothelin-1 plays a role in the elevation
of blood pressure and in vascular hypertrophy in the
DOCA-salt hypertensive rat model.
Further evidence that blockade of endothelin recep-
tors by bosentan decreases blood pressure and inhibits
vascular hypertrophy came from a study of spontane-
ously hypertensive stroke-prone rats (SHRSP).20
SHRSP were administered bosentan in their diet start-
ing at 3 months of age. Untreated SHRSP and un-
treated Wistar-Kyoto (WKY) rats served as controls.
Bosentan-treated rats had lower mean systemic blood
pressure, and lower systolic, diastolic, pulse, and
mean pressures in arterioles in the cerebrum than did
untreated SHRSP. These blood pressures were still
significantly higher than those in WKY rats (Table 1).
Measurements of first-order arterioles in the cerebrum
were made when the animals reached 6 months of age.
The cross-sectional area of the vessel wall was signif-
icantly larger in SHRSP than in WKY, but in bosentan-
treated SHRSP the area was not significantly different
from the area in WKY rats (Table 1). That is, treatment
with bosentan prevented hypertrophy in cerebral ar-
terioles without normalizing either mean systemic
pressure or pulse blood pressure. However, bosentan
did not have any significant effects on internal or
external diameters of arterioles in SHRSP. A number
FIGURE 4. Lumen diameter (mm) and
media:lumen ratio (expressed as a percent-
age) of resistance arteries in uninephrec-
tomized control rats (Uni-Nx), DOCA-
salt hypertensive rats (DOCA), and
DOCA-salt hypertensive rats adminis-
tered bosentan.
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of factors have been postulated as contributing to the
cerebral vascular hypertrophy and remodeling that
occurs during hypertension, including the increased
blood pressure itself, angiotensin II and other neuro-
hormonal factors, and genetic factors. This study
shows that bosentan, an antagonist of both ETA and
ETB, prevents hypertrophy of arterioles in the cere-
brum in SHRSP, which suggests that endothelin-1
contributes to the hypertrophy of cerebral arteries oc-
curring during hypertension. This effect may not ap-
ply to all arteries under all conditions. In a study by Li
and Schiffrin, endothelin receptor blockade did not
significantly affect hypertrophy in small mesenteric,
coronary, renal, or femoral arteries.21 This could be
due to several differences in the studies. Endothelin-1
may contribute to hypertrophy of cerebral arteries, but
not to all other arteries. It is also possible that the effect
may only be significant in blood vessels above a cer-
tain size, or when blood pressure rises above some
threshold.
Bosentan has also been studied in patients with
heart failure, in whom plasma endothelin-1 levels are
commonly elevated.22 These patients all had conges-
tive heart failure of .3 months’ duration. Endothe-
lin-1 concentrations were above normal in all patients
and correlated with the extent of pulmonary hyper-
tension, with left and right heart-filling pressures,
with pulmonary vascular resistance, and, inversely
with cardiac index. Plasma big endothelin-1 levels
were also above normal. This was a randomized, dou-
ble-blind study in which patients received two intra-
venous infusions of either placebo or bosentan (100
mg followed 60 min later by 200 mg). All patients
were previously on regimens consisting of angiotensin
converting enzyme inhibitors (24), diuretics (20),
digoxin (15), calcium antagonists (2), low-dose
b-blockers (3), long-acting nitrates (9), and antiar-
rhythmic drugs, which were withheld prior to infu-
sions. Hemodynamics and plasma endothelin-1 con-
centrations were determined before and during the
120-min infusion. Bosentan reduced mean pulmonary
artery pressure by 13.7% compared to the effects of
placebo (Figure 5). It also lowered mean arterial blood
pressure by 7.7%, right atrial pressure by 18.2%, and
pulmonary artery wedge pressure by 8.6%, all com-
pared to results shown by placebo. It increased the
cardiac index by 13.6% (Figure 6), but did not change
the heart rate. Consequently, calculated systemic vas-
cular resistance fell by 16.5% and pulmonary vascular
resistance by 33.2% (P , .01 for both). Most of the
effect was seen after the first (100 mg) infusion. Plasma
endothelin-1 levels rose significantly in the patients
receiving bosentan from a mean of 38.9 pg/mL to 89.6
pg/mL. Big endothelin-1, norepinephrine, angiotensin
TABLE 1. MEAN SYSTEMIC ARTERIAL PRESSURE,
PULSE PRESSURE, AND VESSEL CROSS-
SECTIONAL AREA IN BOSENTAN-TREATED
RATS AND CONTROLS
Parameter WKY SHRSP-U SHRSP-B
Systemic arterial
mean pressure,
mm Hg 90 6 3 183 6 3* 152 6 5*†
Pulse pressure,
mm Hg 25 6 3 40 6 2* 33 6 2*†
Cross-sectional
area of vessel
wall, mm2 1299 6 65 1627 6 173* 1287 6 78†
Values are mean 6 SEM
WKY, Wistar-Kyoto rats; SHRSP-U, spontaneously hypertensive stroke-
prone rats, untreated; SHRSP-B, spontaneously hypertensive stroke-prone
rats, bosentan-treated.
* P , .05 v WKY; †P , .05 v untreated SHRSP.
Reprinted with permission from Chillon J et al.20
FIGURE 5. Change from baseline in pulmonary arterial pres-
sure (mean 6 SEM) after infusion with bosentan or placebo in
patients with CHF (congestive heart failure). Reprinted with per-
mission from Kiowski W et al.22
FIGURE 6. Change from baseline in cardiac output (mean 6
SEM) after infusion with bosentan or placebo in patients with
CHF (congestive heart failure). Reprinted with permission from
Kiowski W et al.22
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II, and renin levels did not change, either in the pla-
cebo group or in patients receiving bosentan. These
results seem to provide strong evidence that endothe-
lin-1 contributes to vascular tone in patients with con-
gestive heart failure.
PLASMA ENDOTHELIN AS A
PROGNOSTIC INDICATOR
Plasma endothelin levels are elevated in the acute
phase of myocardial infarction (MI) and in chronic
heart failure. To test whether plasma endothelin con-
centration is predictive of subsequent mortality, Om-
land et al23 related it to 1-year mortality after docu-
mented myocardial infarction. Blood samples from
142 patients in the subacute phase following myocar-
dial infarction were assayed for endothelin 3 days
after the onset of symptoms. Plasma endothelin was
5.6 6 0.3 pg/mL (mean 6 SEM) in the patients with
myocardial infarction compared to 3.7 6 0.3 pg/mL in
controls (P 5 .05), who were patients admitted to
hospital with acute chest pain but without evidence of
myocardial necrosis. Of the 142 MI patients, those who
had clinical heart failure during their hospitalization
had significantly higher plasma endothelin concentra-
tions than those without evidence of heart failure
(7.2 6 0.8 v 4.9 6 0.2 pg/mL, P , .001). At the
conclusion of the 1-year follow-up, the day 3 plasma
endothelin level of survivors was found to have been
5.1 6 0.2 pg/mL (mean 6 SEM). In comparison, pa-
tients who died of cardiac causes during this 1-year
period had endothelin levels of 9.2 6 1.5 pg/mL,
which was significantly higher (P , .001). Analysis by
a Cox proportional-hazards model revealed that
plasma endothelin level was strongly related to sur-
vival (P , .0001). Comparison with variables previ-
ously determined to be associated with a poor prog-
nosis, eg, age, male sex, and previous history of an-
gina, systemic hypertension, or MI, found that, with
the exception of male sex, none of these variables
provided additional information after introduction of
plasma endothelin in a multivariate model (Table 2).
SUMMARY
Endothelins are a family of 21–amino-acid peptides
having potent vasoconstrictive effects. They bind to
specific receptors, ETA and ETB, on smooth muscle
and endothelial cells. Endothelin-1 is the best studied
of this family, but its role in hypertension and other
pathologies is still not well understood. When admin-
istered to animals it causes severe vasoconstriction,
but plasma levels are not significantly elevated in
hypertension. Recent studies have reported a syner-
gistic hypertensive effect of endothelin-1 and angio-
tensin II, but not between endothelin-1 and norepi-
nephrine. Endothelin receptor blockade has lowered
blood pressure and reduced the cross-sectional area of
neointima both in hypertensive rats and after vascular
injury. Infusion of the nonspecific endothelin receptor
antagonist bosentan in patients with congestive heart
failure decreased blood pressure, increased cardiac
index, and reduced vascular resistance. Plasma endo-
thelin-1 levels were found to have a significance at
least equal to known risk factors in predicting the
1-year survival rate of patients after myocardial infarc-
tion. While endothelin-1 alone is not thought to be an
independent factor in the development of hyperten-
sion or associated end-organ damage and pathology,
there is increasing evidence that it may play a signif-
icant role in such processes and may offer an impor-
tant pathway for therapeutic intervention. The re-
cently developed endothelin receptor antagonist
bosentan appears promising in this regard.
REFERENCES
1. Li J, Lariviere R, Schiffrin E: Effect of a nonselective
endothelin antagonist on vascular remodeling in de-
oxycorticosterone acetate-salt hypertensive rats. Hy-
pertension 1994;24:183–188.
2. Mortensen L, Pawloski C, Kanagy N, et al: Chronic
hypertension produced by infusion of endothelin in
rats. Hypertension 1990;15:729–733.
3. Yanagisawa M, Kurihara H, Kimura S, et al: A novel
potent vasoconstrictor peptide produced by vascular
endothelial cells. Nature 1988;332:411–415.
4. Kaajager K, Shaw S, Koomans H, et al: Role of endo-
thelin receptor subtypes in the systemic and renal re-
sponses to endothelin-1 in humans. J Am Soc Nephrol
1997;8:32–39.
5. Schiffrin E, Thibault G: Plasma endothelin in human
essential hypertension. Am J Hypertens 1991;4:303–308.
6. Kohno M, Murakawa K, Horio T, et al: Plasma immu-
noreactive endothelin-1 in experimental malignant hy-
pertension. Hypertension 1991;18:93–100.
7. Lariviere R, Thibault G, Schiffrin E, et al: Increased
endothelin-1 content in blood vessels of deoxycortico-
sterone acetate-salt hypertensive but not in spontane-
ously hypertensive rats. Hypertension 1993;21:294–300.
TABLE 2. MULTIVARIATE RELATION BETWEEN
VARIOUS DEMOGRAPHIC, CLINICAL, AND
BIOCHEMICAL VARIABLES AND 1-YEAR
MORTALITY AFTER MYOCARDIAL INFARCTION




Atrial natriuretic factor .2808*
Age .8271*
Male sex 21.4625 .0066
Systemic hypertension .1483*
In-hospital heart failure .4945*
* Factors not included in the model.
Reprinted with permission from Omland T et al.23
AJH–APRIL 1998–VOL. 11, NO. 4, PART 3108S BRUNNER
8. Deng Y, Luscher T: Endothelin in hypertensive resis-
tance arteries intraluminal and extraluminal dysfunc-
tion. Hypertension 1991;18:543–549.
9. Rakugi H, Tabuchi Y, Nakamaru M, et al: Endothelin
activates the vascular renin-angiotensin system in rat
mesenteric arteries. Biochem Int 1990;21:867–872.
10. Yoshida K, Yasujima M, Kohzuki M, et al: Endothelin-1
augments pressor response to angiotensin II infusion in
rats. Hypertension 1992;20:292–297.
11. Yasujima, Abe K, Kohzuki M, et al: Atrial natriuretic
factor inhibits the hypertension induced by chronic
infusion of norepinephrine. Circ Res 1985;57:470–474.
12. Tabuchi Y, Nakamaru M, Rakugi H: Effects of endo-
thelin on neuroeffector junction in mesenteric arteries
of hypertensive rats. Hypertension 1990;15:739–743.
13. Libby P, et al: A cascade model for restenosis: a special
case of atherosclerosis progression. Circulation 1992;
86(suppl III):47–52.
14. Douglas S, Louden C, Vickery-Clark L, et al: A role for
endogenous endothelin-1 in neointimal formation after
rat carotid artery balloon angioplasty. Circ Res 1994;75:
190–197.
15. Zamora M, Dempsey E, Walchak S, et al: BQ123, an
ETA receptor antagonist, inhibits endothelin-1-medi-
ated proliferation of human pulmonary artery smooth
muscle cells. Am J Respir Cell Mol Biol 1993;9:429–433.
16. Ohlstein E, Douglas S, Sung C, et al: The selective ETA
receptor antagonist BQ123 antagonizes endothelin-1-
mediated mitogenesis. Eur J Pharmacol 1992;225:347–
350.
17. A¨nggård E, et al: The fate of radioiodinated endothe-
lin-1 and endothelin-3 in the rat. J Cardiovasc Pharma-
col 1989;13(suppl 5):S46–S49.
18. Waggoner W, Genova S, Rash V: Kinetic analyses dem-
onstrate that equilibrium assumption does not apply to
[125I] endothelin-1 binding data. Life Sci 1992;51:1869–
1876.
19. Bazil M, et al: Pharmacologic characterization of an
endothelin-A (ETA) receptor antagonist in conscious
rats. J Cardiovasc Pharmacol 1993;20:940–948.
20. Chillon J, Heistad D, Baumbach G: Effects of endothelin
receptor inhibition on cerebral arterioles in hyperten-
sive rats. Hypertension 1996;27(part 2):794–798.
21. Li J, Schiffrin E: Effect of chronic treatment of adult
spontaneously hypertensive rats with an endothelin
receptor antagonist. Hypertension 1995;25:495–500.
22. Kiowski W, Sutsch G, Hunziker P, et al: Evidence of
endothelin-1-mediated vasoconstriction in severe
chronic heart failure. Lancet 1995;346:732–736.
23. Omland T, Lie R, Aakvaag A, et al: Plasma endothelin
determination as a prognostic indicator of 1-year mor-
tality after acute myocardial infarction. Circulation
1994;89:1573–1579.
AJH–APRIL 1998–VOL. 11, NO. 4, PART 3 ENDOTHELIN INHIBITION AND HYPERTENSION 109S
